EGFR and non-small cell lung carcinoma: Studies also found adaptive reactivation of signal transducer and activator of transcription 3 (STAT3) within the minimal residual surviving drug persister tumor cells, which was co-activated with the SRC-YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC [56].